Surrey Heartlands

Joint Formulary & PAD

Fluticasone with umeclidinium and vilanterol (Trelegy Ellipta) - Chronic Obstructive Pulmonary Disease (COPD)

You are here : Home > Formulary Search > Fluticasone with umeclidinium and vilanterol (Trelegy Ellipta) - Chronic Obstructive Pulmonary Disease (COPD)

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Green
Formulations :
  • Inhaler (dry powder)
Formulary Status :
Primary Care
ASPH
RSFT
SASH
SABP
Associated Icons :
Guidelines BNF SPC
Restrictions / Comments :

Documentation

Guidelines (Local)
COPD Primary Care Medicines Management Guidelines - updated Jun 23
Guidelines (National)
NICE NG115 COPD diagnosis and management

PAD Profile

ChemicalSubstance :
Fluticasone with umeclidinium and vilanterol (Trelegy Ellipta)
Indication :
Chronic Obstructive Pulmonary Disease (COPD)
Group Name :
Triple therapy
Keywords :
LABA beta agonist, long acting, ICS, antimuscarinic, triple therapy
Brand Names Include :
Trelegy Ellipta
Important Information :
Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Chronic Obstructive Pulmonary Disease (COPD)
Supporting Documents :
2

Other Indications

Below are listed other indications that Fluticasone with umeclidinium and vilanterol (Trelegy Ellipta) is used to treat.

  • No records returned.

Other Drugs

Below are listed other drugs that are used to treat Chronic Obstructive Pulmonary Disease (COPD).

Committee Recommendations (1)

07 Jun 23 - Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

The locally preferred triple-therapy devices for COPD are as follows:

Low carbon:

  • Trimbow NEXThaler (dry powder)
  • Trelegy Ellipta (dry powder)

Alternative devices:

  • Trimbow (pMDI). To be used with a spacer.

Triple therapy combination inhalers are recommended as a treatment option in COPD, where clinically appropriate, in line with NICE guidance (NG115 –updated July 2019) and GOLD guidelines.

See local COPD guidelines for further details